In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Adaptimmune Therapeutics PLC

www.adaptimmune.com

Latest From Adaptimmune Therapeutics PLC

Deal Watch: Ireland's Amryt Acquires Aegerion

European firms Amryt and Evotec have signed agreements to acquire two companies based across the Atlantic – Aegerion and Just Biotherapeutics, respectively. 

Deals M & A

Deal Watch: Parvus Signs Second Big Pharma Alliance, With Genentech

Two years after its first big Navacim-based tie-up with Novartis, Parvus could earn beyond $800m in autoimmune R&D pact with Genentech. Iconic licenses ADC tech from Zymeworks, then out-licenses lead candidate to Exelixis.

Deals Business Strategies

J.P. Morgan 2019: Biopharma Sentiment Soars As Deal And Financing Optimism Abounds

Biopharma investor sentiment plunged at the end 2018, but soared as the J.P. Morgan Healthcare Conference kicked off with another big company acquisition and as industry participants indicated their optimism about financing and deal-making opportunities in 2019.

Deals Financing

Lessons From A Life Sciences Lifetime: An Interview With Sir John Bell

Professor Sir John Bell talks to In Vivo about how the life sciences sector has evolved during his career, lessons he has learned along the way, and the biggest challenges and changes ahead for the industry in 2019.

Leadership Outlook 2019
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Adaptimmune Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Adaptimmune Therapeutics PLC
  • Senior Management
  • James Noble, CEO
    Adrian Rawcliffe, CFO
    Rafael Amado, MD, Pres., R&D
    Helen Tayton-Martin, PhD, CBO
    William Bertrand, COO
  • Contact Info
  • Adaptimmune Therapeutics PLC
    Phone: (44) 1235 430000
    60 Jubilee Ave.
    Milton Park
    Abingdon, OX14 4RX
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register